Can a common diabetes drug work safely in kidney patients?

NCT ID NCT02895750

Completed Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tested the safety and effectiveness of metformin extended release (XR) in 12 adults with type 2 diabetes and mild to moderate chronic kidney disease (stages 1 to 3). Participants took metformin XR tablets for 6 to 12 weeks, and researchers monitored their blood glucose levels continuously. The goal was to see if the drug could control blood sugar without causing harm, especially to the kidneys.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: metformin extended release (XR)
What this could lead to: If successful, this could show that metformin XR is safe and effective for managing blood sugar in type 2 diabetes patients with mild to moderate kidney disease.
What could go wrong: This is a small, early-phase study with only 12 participants, so results may not apply broadly. Metformin can rarely cause lactic acidosis, especially in kidney disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL INSUFFICIENCY CHRONIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL INSUFFICIENCY CHRONIC

Contacts and locations

Locations

CHU Amiens Picardie

Amiens, 80054, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.